Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs SLNO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLNO Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

SLNO Overall Winner 6-Pillar Tally: ZLAB 1 – 5 SLNO Matrix Metrics: ZLAB 3 – 7 SLNO

As of Nov 16, 2026, Soleno Therapeutics, Inc. (SLNO) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas SLNO carries 44.5/100 (HOLD) at $53.01 (8.4x Forward P/E, 33.6% operating margin).

  • Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. SLNO 44.5/100 HOLD), SLNO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (33.6% vs. -63.0% operating margin) and revenue trajectory (+0.0% vs. -6.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs SLNO
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
SLNO NASDAQ Head-to-Head Winner
Soleno Therapeutics, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$53.01
+0.04% 1D
Market Cap $2.8B
TTM Revenue $285M
Forward P/E 8.4x
Beta / 30D Vol 1.23β · 2% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 40.0 Flow 51.0 Mom 25.9
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (13.6% over 20 days), RSI 78
RSI-14: 78.3 · SMA20: $52.86 · SMA50: $45.52

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 1 – 5 SLNO)

Columns: Metric · ZLAB · SLNO
1. Valuation Multiples SLNO
Forward P/E N/M 8.4x
Trailing P/E N/M 27.5x
PEG Ratio N/M N/M
EV / Revenue 6.8x 9.7x
2. Growth & Scale ZLAB
Revenue Growth (YoY) -6.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $442M $285M
Market Cap $3.0B $2.8B
3. Profitability & Quality SLNO
Gross Margin 0.6% 98.6%
Operating Margin -63.0% 33.6%
Net Profit Margin -44.9% 33.7%
Return on Equity (ROE) -30.0% 26.4%
4. Balance Sheet & Cash Flow SLNO
Cash Generation (TTM) -$262M EBITDA $92M EBITDA
Cash Flow Margin -59.3% EBITDA Mgn 32.1% EBITDA Mgn
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $8.61 Book/Sh · 26.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLNO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 58.4% (58th %ile) 0.9% (<1st %ile)
Put/Call OI Skew Thin ADR Chain 5.23x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat SLNO
OpEx & R&D Intensity 63.6% of Rev ($281M) 65.0% of Rev ($185M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (3) vs SLNO (7)
Institutional Metric ZLAB SLNO Criterion Row Edge
Market Capitalization
Scale
$3.0B $2.8B Larger Scale ZLAB
Trailing P/E Ratio
Valuation
N/M 27.5x Lower Multiple SLNO
Forward P/E Ratio
Valuation
N/M 8.4x Lower Multiple SLNO
Revenue Growth (YoY)
Growth
-6.8% +0.0% Higher Growth SLNO
Operating Margin (TTM)
Profitability
-63.0% 33.6% Higher Margin SLNO
Net Profit Margin
Profitability
-44.9% 33.7% Higher Margin SLNO
Return on Equity (ROE)
Capital Efficiency
-30.0% 26.4% Higher ROE SLNO
52-Week Range Position
Momentum
60% ($16–$29) 39% ($29–$90) Stronger Trend ZLAB
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 1.23β · 2% Vol Lower Realized Risk SLNO
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite ZLAB
Trailing 12M Revenue (USD)
Operating Scale
$442M $285M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% 98.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · 9.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) $92M EBITDA ($8.61 Book/Sh · 26.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLNO +13.22 pp
ZLAB: -12.38% · SLNO: +0.84%
3M Horizon SLNO +39.55 pp
ZLAB: +2.8% · SLNO: +42.35%
6M Horizon SLNO +17.2 pp
ZLAB: -5.25% · SLNO: +11.95%
1Y Horizon SLNO +17.2 pp
ZLAB: -5.25% · SLNO: +11.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs SLNO. Trailing 12-month operating profitability (ZLAB -63.0% vs SLNO 33.6%) and valuation multiples (ZLAB N/M vs SLNO 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
SLNO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$285M
Gross Margin98.6%
Op. Margin33.6%
ROE / Fwd P/E26.4% · 8.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLNO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.9%
IV Percentile <1st %ile
Put/Call OI Skew 5.23x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SLNO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
SLNO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $2.8B market capitalization and 33.6% operating margin.
OpEx & R&D Reinvestment 65.0% of Rev ($185M)
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs SLNO Key Questions & Quantitative Answers

As of Nov 16, 2026, Soleno Therapeutics, Inc. (SLNO) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas SLNO carries 44.5/100 (HOLD) at $53.01 (8.4x Forward P/E, 33.6% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. SLNO 44.5/100 HOLD), SLNO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (33.6% vs. -63.0% operating margin) and revenue trajectory (+0.0% vs. -6.8% YoY).

ZLAB leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with SLNO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $285M TTM revenue (98.6% gross margin, 33.6% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $285M for SLNO. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 65.0% of Rev ($185M) (0 disclosures) for SLNO.

SLNO screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas SLNO trades at 8.4x Forward P/E, 27.5x Trailing P/E, N/M PEG, and 9.7x EV/Revenue (32.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus SLNO (26.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, SLNO carries 0.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 5.23x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.